Outlook Therapeutics
OTLK
15 hedge funds and large institutions have $21.1M invested in Outlook Therapeutics in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
26.97% more ownership
Funds ownership: 0% → 26.97% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$7.71M |
| 2 |
Perceptive Advisors
New York
|
+$4.89M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.83M |
| 4 |
Avoro Capital Advisors
New York
|
+$1.74M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$966K |
Top Sellers
OTLK Hedge Fund Activity: Q2 2016 in Review
15 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2016, worth a combined $21.1M.
Buyers outnumbered sellers: 15 funds opened new OTLK positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $7.71M.
- 15 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $21.1M of Outlook Therapeutics stock for Q2 2016.
- 15 funds opened new Outlook Therapeutics positions in Q2 2016 and 0 closed out, a net change of +15 holders.
- The largest Outlook Therapeutics buyer in Q2 2016 was Sabby Management, an estimated $7.71M added.
Based on aggregated 13F filings for Q2 2016.